Protein Kinase Inhibitors 1

<strong>Protein Kinase Inhibitors 1</strong>_x000D_ <strong>Catalog number:</strong> B2018466_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 419.89 g/mol_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8 °C_x000D_ <strong>Keywords:</strong> (Z)-5-((2-oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis Int J Cancer. 2017 Jun 15;140(12):2805-2819._x000D_ 2: Abdelgalil AA, Al-Kahtani HM, Al-Jenoobi FI. Erlotinib Profiles Drug Subst Excip Relat Methodol. 2020;45:93-117._x000D_ 3: Steins M, Thomas M, Geißler M. Erlotinib Recent Results Cancer Res. 2018;211:1-17._x000D_ 4: Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer J Clin Oncol. 2023 Feb 10;41(5):1105-1115._x000D_ 5: Luo MY, Zhou Y, Gu WM, Wang C, Shen NX, Dong JK, Lei HM, Tang YB, Liang Q, Zou JH, Xu L, Ma P, Zhuang G, Bi L, Xu L, Zhu L, Chen HZ, Shen Y. Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma Cancer Res. 2022 Oct 4;82(19):3516-3531._x000D_ 6: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 2011 Aug;12(8):735-42._x000D_ 7: Ge W, Wang Y, Quan M, Mao T, Bischof EY, Xu H, Zhang X, Li S, Yue M, Ma J, Yang H, Wang L, Yu Z, Wang L, Cui J. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib Mol Cancer. 2024 Mar 8;23(1):48._x000D_ 8: Truong DT, Ho K, Nhi HTY, Nguyen VH, Dang TT, Nguyen MT. Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations Sci Rep. 2024 May 28;14(1):12218._x000D_ 9: Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines Clin Pharmacokinet. 2011 Jun;50(6):371-403._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/21196266">10: Colabufo NA, Contino M, Niso M, Berardi F, Leopoldo M, Perrone R. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1811-23. </a>_x000D_ _x000D_ <strong>Products Related to Protein Kinase Inhibitors 1 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>